Experience with carbon-11 choline positron emission tomography in prostate carcinoma

被引:178
作者
Kotzerke, J
Prang, J
Neumaier, B
Volkmer, B
Guhlmann, A
Kleischmidt, K
Hautmann, R
Reske, SN
机构
[1] Univ Ulm, Dept Nucl Med, D-89069 Ulm, Germany
[2] Univ Ulm, Dept Urol, D-89069 Ulm, Germany
关键词
choline; positron emission tomography; prostate cancer; staging;
D O I
10.1007/s002590000309
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We investigated the potential of carbon-ii choline positron emission tomography (PET) for the detection of lymph node and bone metastases in prostate cancer. A total of 23 patients were studied (known metastases: 8; suspicion of metastases: 3; primary staging: 12). Whole-body PET imaging was performed 5 min after injection of the tracer and completed within 1 h. Focally increased tracer uptake in bone or abdominal lymph node regions was interpreted as representing tumour involvement. All known bone and lymph node metastases could be recognized by [C-11]choline PET. One out of ten negative scans for primary staging was false-negative (lymph node <1 cm) and one out of two positive scans was false-positive with regard to lymph node involvement (focal bowel activity). It is concluded that [C-11]choline PET is a promising new tool for the primary staging of prostate cancer, with lymph node and bone metastases demonstrating high tracer uptake. Therapeutic management could be influenced by these results in that the technique may permit avoidance of surgical lymph node exploration.
引用
收藏
页码:1415 / 1419
页数:5
相关论文
共 10 条
[1]   Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography [J].
Deloar, HM ;
Fujiwara, T ;
Nakamura, T ;
Itoh, M ;
Imai, D ;
Miyake, M ;
Watanuki, S .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (06) :629-633
[2]   Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose [J].
Effert, PJ ;
Bares, R ;
Handt, S ;
Wolff, JM ;
Bull, U ;
Jakse, G .
JOURNAL OF UROLOGY, 1996, 155 (03) :994-998
[3]  
FRIEDLAND RP, 1983, J NUCL MED, V24, P812
[4]   Combating prostate cancer [J].
Garnick, MB ;
Fair, WR .
SCIENTIFIC AMERICAN, 1998, 279 (06) :74-83
[5]  
GAUTHIER S, 1985, CAN J NEUROL SCI, V12, P214
[6]  
Hara T, 1997, J NUCL MED, V38, P842
[7]  
Hara T, 1998, J NUCL MED, V39, P990
[8]   Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma [J].
Kotzerke, J ;
Guhlmann, A ;
Moog, F ;
Frickhofen, N ;
Reske, SN .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (01) :31-38
[9]   Prostate cancer: Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging [J].
Kurhanewicz, J ;
Vigneron, DB ;
Hricak, H ;
Parivar, F ;
Nelson, SJ ;
Shinohara, K ;
Carroll, PR .
RADIOLOGY, 1996, 200 (02) :489-496
[10]   Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer [J].
Seltzer, MA ;
Barbaric, Z ;
Belldegrun, A ;
Naitoh, J ;
Dorey, F ;
Phelps, ME ;
Gambhir, SS ;
Hoh, CK .
JOURNAL OF UROLOGY, 1999, 162 (04) :1322-1328